ICU Medical (NASDAQ:ICUI) and Otsuka Pharmaceutical Factory, a unit of Japan’s Otsuka, are launching a joint venture focused ...

Otsuka’s IV solutions subsidiary, Otsuka Pharmaceutical Factory, is breaking into the North American market with the help of ...

Otsuka Holdings will pay ICU Medical an upfront payment of $200 million. The U.S. IV products market has seen ...

Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...

Otsuka Holdings Co (JP:4578) has released an update. Otsuka Pharmaceutical Factory America, a subsidiary of Otsuka Pharmaceutical Factory, has ...

Otsuka Pharmaceutical Factory and ICU Medical have formed a $200 million joint venture to bolster the US IV product supply ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

ICU Medical (ICUI) and Otsuka Pharmaceutical Factory, global IV solutions manufacturing subsidiary of Otsuka Holdings Co., Ltd., together announce the creation of a joint venture to provide additional ...

Otsuka Pharmaceutical’s kidney disease drug has hit the primary endpoint of a phase 3 trial by demonstrating in an interim analysis the reduction of patients’ urine protein-to-creatine ratio ...

ICU Medical (NASDAQ:ICUI) and Otsuka Pharmaceutical Factory, a unit of Japan’s Otsuka, are launching a joint venture focused on boosting IV solutions production and development in North America.

ICU Medical (ICUI) and Otsuka Pharmaceutical Factory, global IV solutions manufacturing subsidiary of Otsuka Holdings Co., Ltd., together announce the creation of a joint venture to provide ...